Abstract
Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.
| Original language | Italian |
|---|---|
| Pages (from-to) | 169-178 |
| Number of pages | 10 |
| Journal | Trends in Medicine |
| Volume | 6 |
| Issue number | 2 |
| Publication status | Published - Apr 2006 |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
- Pharmacology (medical)
Cite this
Orlistat e rischio cardiovascolare. / Derosa, Giuseppe; Piccinni, Mario N.
In: Trends in Medicine, Vol. 6, No. 2, 04.2006, p. 169-178.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Orlistat e rischio cardiovascolare
AU - Derosa, Giuseppe
AU - Piccinni, Mario N.
PY - 2006/4
Y1 - 2006/4
N2 - Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.
AB - Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.
KW - Cardiovascular risk
KW - Diabetes
KW - Obesity
KW - Orlistat
KW - Weight reduction
UR - http://www.scopus.com/inward/record.url?scp=33646511113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646511113&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:33646511113
VL - 6
SP - 169
EP - 178
JO - Trends in Medicine
JF - Trends in Medicine
SN - 1594-2848
IS - 2
ER -